Prediction of the extent and severity of left ventricular dysfunction in anterior acute myocardial infarction by the admission electrocardiogram - 03/09/11
Abstract |
Background The grade of ischemia, as detected by the relation between the QRS complex and ST segment on the admission electrocardiogram, is associated with larger infarct size and increased mortality rates in acute myocardial infarction. Methods We assessed the correlation between left ventricular function and the admission electrocardiogram in 151 patients with first anterior acute myocardial infarction who received thrombolytic therapy and underwent cardiac catheterization at 90 minutes and before hospital discharge. The number of leads with ST elevation, sum of ST elevation, maximal Selvester score, and the presence of severe (grade 3) ischemia were determined in each electrocardiogram. Left ventricular ejection fraction, the number of chords with wall motion abnormalities, and the severity of dysfunction (SD/chord) were determined. Results At 90 minutes, the 39 ischemia grade 3 patients had lower ejection fraction than the 112 grade 2 patients. Both at 90 minutes and at hospital discharge, the grade 3 group had more chords with wall motion abnormalities and more severe regional dysfunction (SD/chord). However, the number of leads with ST elevation, sum of ST elevation, and maximal Selvester score had no correlation with ejection fraction at 90 minutes and only mild correlation with the extent of dysfunction (number of chords) at 90 minutes. There was no correlation between either the number of leads with ST elevation or the sum of ST elevation and the severity of regional dysfunction. Conclusions The number of leads with ST elevation, sum of ST elevation, and maximal Selvester score had only mild correlation with the extent of myocardial dysfunction but not with the severity of dysfunction. Grade 3 ischemia is predictive of more extensive myocardial involvement and greater severity of regional dysfunction. (Am Heart J 2001;141;915-24.)
Le texte complet de cet article est disponible en PDF.Plan
☆ | Reprint requests: Yochai Birnbaum, MD, Cardiac Intensive Care Unit, Division of Cardiology, Rabin Medical Center, Campus Beilinson, Petah-Tiqva, Israel. E-mail: birnbaum@post.tau.ac.il |
☆☆ | Guest Editor for this manuscript was Gary S. Francis, MD, Cleveland Clinic Foundation, Cleveland, Ohio. |
★ | The GUSTO-I study was funded by Bayer Corporation, New York, NY; CIBA-Corning, Inc, Medfield, Mass; Genentech, Inc, South San Francisco, Calif; ICI Pharmaceuticals, Inc, Wilmington, Del; and Sanofi Pharmaceuticals, Paris, France. |
Vol 141 - N° 6
P. 915-924 - juin 2001 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?